



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington DC 20231 on

March 14, 2002.

Deine L. Newton

Dated: March 14, 2002

PF82PCTSEQ/dln

Applicant

Christine ANDREOUI, et al.

Title

USE OF ACTIVE P40 CONJUGATES FOR NASAL

DELIVERY

Serial No.

09/647,309

BEST AVAILABLE

Filing Date

January 3, 2001

Examiner

Iesha Fields

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY AND SUBMISSION OF SUBSTITUTE SEQUENCE LISTING IN PAPER FORM AND COMPUTER READABLE FORM

Sir:

Responsive to the Notice to Comply of February 20, 2002, herewith please find a substitute Sequence Listing in both computer readable form and paper form. The substitute Sequence Listing corrects the defects found in the first submission.

A Statement under 37 CFR 1.821(f) is also enclosed.

BEST AVALLE CO.

Entry of the Sequence Listing and Statement into the record are hereby respectfully requested.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

G. PATRICK SAGE, Attorney #37,710

Dated: March 14, 2002 Customer No. 25,666 500 Columbia Plaza 350 East Michigan Avenue Kalamazoo, MI 49007 (616) 382-0030

Enclosure: Return Postal Card Receipt

Sequence Listing in computer readable format

Sequence Listing in paper format Statement under 37 CFR 1,821(f)

Copy of Notice to Comply



BEST AVANDA CULT

PF82PCTSEQ/dln

Applicant

Christine ANDREOUI, et al.

Title

USE OF ACTIVE P40 CONJUGATES FOR NASAL

DELIVERY

Serial No.

09/647,309

Filing Date

January 3, 2001

Examiner

lesha Fields

* * * *

RECEIVED
MAR 2 6 2002

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

STATEMENT UNDER 37 CFR 1.821(f)

The undersigned attorney does hereby state that, to the best of his knowledge and understanding, the accompanying substitute Sequence Listing in computer readable form is the same as the accompanying substitute Sequence Listing in paper copy form.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By:

G. PATRICK SAGE, #37,710

Dated: March 14, 2002 Customer No: 25,666 500 Columbia Plaza

350 East Michigan Avenue

Kalamazoo, MI 49007

616-382-0030

Enclosure: Sequence Listing in CD-ROM form and paper form

MAR 2 1 2002

CEST AVAILABLE COPY

Application No.: 09 647 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. Revever, the content of the computer readable form does not comply with the requirements of 37°C.F.R. 1.82°C and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Disting."
X	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the ∞mputer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Ąpp	licant Must Provide:
À '	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
Ø.	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry nto the specification.
1	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or .825(b) or 1.825(d). Questions regarding compliance to these requirements, please contact:
For F For (Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 Patentln software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE